All In Biotech

Drug Trial Radar · NCT01371630

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

276

Planned (sponsor's estimate)

Start

Aug 26, 2011

Primary completion

Dec 25, 2027

Study completion Dec 25, 2027

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jun 13, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin together with combination chemotherapy may be a better treatment for acute lymphoblastic leukemia.

Conditions

  • B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • Burkitt-Like Lymphoma With 11q Aberration
  • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Recurrent B Acute Lymphoblastic Leukemia
  • Recurrent Burkitt Lymphoma
  • Refractory B Acute Lymphoblastic Leukemia
  • Refractory Burkitt Lymphoma

Interventions

  • BlinatumomabBiological

    Given CIVI

  • CyclophosphamideDrug

    Given IV

  • CytarabineDrug

    Given IT and IV

  • DexamethasoneDrug

    Given IV or PO

  • Inotuzumab OzogamicinBiological

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • MercaptopurineDrug

    Given PO

  • MethotrexateDrug

    Given IT, IV, and PO

  • PrednisoneDrug

    Given PO

  • RituximabBiological

    Given IV

  • VincristineDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose of inotuzumab ozogamicin based on incidence of dose limiting toxicities (Phase I)Time frame: 28 days
  2. Progression free survival (PFS) in frontline elderly acute lymphoblastic leukemia (ALL) (Phase II)Time frame: 2 years
  3. Response rate in refractory-relapsed acute lymphoblastic leukemia (ALL) (Phase II)Time frame: Up to 5 years
  4. Survival in refractory-relapsed acute lymphoblastic leukemia (ALL) (Phase II)Time frame: Up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • M D Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.